Fibro-inflammation Focus Target pipeline opportunities in fibro-inflammatory diseases with a emphasis on fibrosis across Crohn's disease and IPF, leveraging Agomab's ALK5/TGFβR1 inhibitors and inhaled delivery capabilities for high local lung exposure.

Phase-Driven Opportunity Capitalize on ongoing Phase 2b and Phase 2 trials (NOV-ERA and INSPIRIA) to position partnering or co-development discussions around patient recruitment support, biomarker strategies, and commercialization planning once data mature.

Strong Funding Promote Agomab's robust funding runway into 2029 as a risk mitigator for potential collaborators, enabling long-term joint development plans and ability to leverage late-stage financing alongside partners.

Strategic Partnerships Leverage recent board appointments and active investor engagement to pursue strategic alliances with larger biotech or pharma players seeking fibrosis and tissue repair franchises, including potential distribution or regional commercialization deals.

Clinical-Access Value Highlight the inhaled, lung-restricted profile of AGMB-447 for IPF as a differentiator to target pulmonology-focused payers and clinical access programs, while offering co-development in fibrosis indications with shared risk and upside.